Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tivic Health Systems ( (TIVC) ) has provided an announcement.
On March 4, 2026, Tivic Health Systems announced that biotech veteran Michael K. Handley had been appointed chief executive officer and director, succeeding founding CEO Jennifer Ernst, who will continue to support the company during the transition. The leadership change is intended to accelerate Tivic’s pivot toward high-growth biopharma opportunities, leveraging Handley’s track record in commercializing late-stage therapies and the company’s Velocity Bioworks unit to advance its immunotherapy pipeline and sharpen its competitive positioning.
Handley’s arrival signals a more aggressive push into late-stage immunotherapies, including the development of Tivic’s lead drug Entolimod and related assets such as Entolasta. For investors and partners, the move underscores Tivic’s ambition to scale its biopharma footprint by combining experienced leadership with integrated contract biomanufacturing capabilities that are expected to support faster development, lower costs and greater supply chain control.
The most recent analyst rating on (TIVC) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Tivic Health Systems stock, see the TIVC Stock Forecast page.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The score is primarily held down by weak financial performance (minimal revenue, persistent losses, and significant cash burn). Technicals also remain bearish with the stock below major moving averages and negative MACD. Strategic progress and improved cash on the earnings update provide partial support, but financing-related leverage/dilution risk and a negative earnings-based valuation keep the overall score low.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a late-stage immunotherapeutics company focused on developing immune-modulating drugs for conditions such as Acute Radiation Syndrome and neutropenia. Its lead candidate, Entolimod, a TLR5 agonist targeting radiation- and age-related cell damage, anchors a pipeline that also includes Entolasta for chronic applications, supported by in-house biomanufacturing via its CDMO subsidiary Velocity Bioworks.
Average Trading Volume: 927,963
Technical Sentiment Signal: Sell
Current Market Cap: $2.01M
Learn more about TIVC stock on TipRanks’ Stock Analysis page.